Alla studier
RekryteringFAS2INTERVENTIONELL

MAVRiC Studies 2L Treatment With AV in Patients With CLL/SLL Who Have Relapsed After a Course of BTKi + BCL2i Combination, With or Without Obinutuzumab

Chronic lymphocytic leukaemia (CLL) and small lymphocytic lymphoma (SLL) are slow-growing cancers affecting white blood cells. Many people respond well to their first treatment, but the condition often returns over time. This study, called MAVRiC, is exploring whether a combination of two targeted drugs—acalabrutinib and venetoclax—can help adults whose leukaemia has come back. It is for people who previously had a similar targeted treatment combination that worked well for at least two years after finishing it. Both drugs work by blocking specific proteins that cancer cells need to survive and grow. Instead of taking treatment indefinitely, participants receive these medicines for a fixed period. Researchers want to see how well the cancer responds and monitor any side effects. Taking part lasts for up to five years, including regular health checks and long-term monitoring.

Överblick

Status
Rekrytering
Fas
FAS2
Sponsor
AstraZeneca
Inskrivningsmål
80
Starta
04 Jun 2026
Beräknad slutförande
23 Mar 2033

Vad handlar denna studie om?

Chronic lymphocytic leukaemia (CLL) and small lymphocytic lymphoma (SLL) are closely related conditions that affect white blood cells called lymphocytes. In these conditions, the body makes too many abnormal white blood cells that do not work properly. While modern targeted treatments can keep the condition under control for years, it is common for the cancer to eventually return.

The MAVRiC study is testing a treatment option for adults whose CLL or SLL has come back. It focuses specifically on people who previously received a combination of targeted medicines that kept the disease in check for at least two years after finishing treatment. Researchers want to find out whether using two targeted drugs, acalabrutinib and venetoclax, can successfully control the condition a second time.

Acalabrutinib and venetoclax attack cancer cells in different ways. Acalabrutinib blocks signals that tell leukaemia cells to multiply, while venetoclax blocks a protein that stops abnormal cells from dying. By taking both together, doctors hope to clear the cancer cells more effectively. Participants receive the drugs for a set period rather than continuously, giving them a planned break from treatment once the course is complete.

Finding safe and reliable second-line treatments is an important goal for doctors caring for people with CLL and SLL. The results of this study will help show whether retreatment with this drug combination is effective, how long the benefits last, and how well patients tolerate the medication.

Viktiga punkter

  • Tests a combination of two targeted drugs: acalabrutinib and venetoclax.
  • Open to adults with CLL or SLL that has returned after successful initial treatment.
  • Treatment is given for a set amount of time rather than continuously.
  • Total study participation lasts up to five years, including follow-up checks.
  • Taking part is voluntary, and you can leave the study at any time.

Vem kan vara berättigad?

This study is open to adults aged 18 and over who have been diagnosed with CLL or SLL that has returned and now requires further medical treatment. To take part, you must have had only one previous course of treatment using a combination of targeted drugs (known as a BTK inhibitor and a BCL2 inhibitor). That initial treatment must have kept your leukaemia well-controlled for at least two years after it finished.

You will need to have routine blood and genetic tests before starting, which help the research team understand the specific features of your leukaemia. You also need to be reasonably active and able to look after yourself in daily life.

You may not be eligible if you have serious heart conditions, severe liver disease, or a history of bleeding disorders. You also cannot take part if you take certain blood-thinning medicines like warfarin, have had major surgery within the last month, or have active infections such as hepatitis or HIV.

Kan denna studie passa dig?

Svara på dessa snabba frågor för att se om du kan vara berättigad. Detta är endast en vägledning — forskarteamet fattar det slutgiltiga beslutet.

  1. I am aged 18 or older.
  2. I have been diagnosed with CLL or SLL that has returned and needs treatment.
  3. My previous treatment was a targeted drug combination that kept my condition stable for at least two years.
  4. I do not have severe heart disease, severe liver disease, or bleeding problems.
  5. I am not currently taking warfarin or other similar blood thinners.
Svara på varje fråga för att se ditt resultat.

Vad innebär deltagande?

If you join the MAVRiC study, your total involvement will last for up to five years. It begins with a screening phase where the medical team runs health checks, scans, and blood tests to make sure the trial is safe for you. During the treatment period, you will take acalabrutinib and venetoclax as prescribed for a fixed duration. You will attend regular hospital appointments for check-ups, blood tests, and scans to see how your body and leukaemia are responding. After finishing the medication, you will enter a follow-up phase where the team monitors your health and keeps track of your recovery over the remaining years.

Potentiella risker och fördelar

Taking part may help shrink your leukaemia and keep it under control without the need for traditional chemotherapy, although there is no guarantee that the treatment will work for everyone. Both acalabrutinib and venetoclax can cause side effects, including an increased risk of infections, low blood counts, bruising, or an upset stomach. Your healthcare team will watch you very closely and provide care to manage any side effects. Joining the study is completely voluntary, and you are free to leave at any time without it affecting your usual NHS medical care.

Platser (47)

  • Forskningsplats
    Verifierat postnummer
    Boston, USA· Rekrytering
  • Forskningsplats
    Verifierat postnummer
    Charlotte, USA· Återkallad
  • Forskningsplats
    Verifierat postnummer
    Charlotte, USA· Rekrytering
  • Forskningsplats
    Verifierat postnummer
    Durham, USA· Rekrytering
  • Forskningsplats
    Verifierat postnummer
    Winston-Salem, USA· Rekrytering
  • Forskningsplats
    Verifierat postnummer
    Horn, Austria· Rekrytering
  • Forskningsplats
    Verifierat postnummer
    Goiânia, Brazil· Rekryterar inte ännu
  • Forskningsplats
    Verifierat postnummer
    Porto Alegre, Brasilien· Rekryterar inte ännu
  • Forskningsplats
    Verifierat postnummer
    Porto Alegre, Brasilien· Rekryterar inte ännu
  • Forskningsplats
    Verifierat postnummer
    São Paulo, Brasilien· Rekryterar inte ännu
  • Forskningsplats
    Verifierat postnummer
    São Paulo, Brasilien· Rekryterar inte ännu
  • Forskningsplats
    Verifierat postnummer
    Brno, Tjeckien· Rekryterar inte ännu

Vanliga frågor

Vad är huvudsyftet med denna studie?

The study tests whether giving two targeted medicines together can safely and effectively control CLL or SLL after it has returned following earlier treatment.

How are the study medicines taken?

Both acalabrutinib and venetoclax are oral medicines taken by mouth, usually as tablets or capsules, for a set period.

Is this trial using chemotherapy?

No. These are targeted therapies designed to block specific proteins inside cancer cells, rather than traditional chemotherapy drugs.

Do I have to pay for the treatment?

No. The trial medicines and any study-related tests or appointments are provided at no cost to you.

What happens if my cancer gets worse during the trial?

Your doctors will monitor your health closely. If the trial treatment stops working, you will be taken off the study drugs and offered alternative care options.

Hur du får reda på mer

AstraZeneca Klinisk Studie Informationscenter

Prata alltid med din läkare eller specialist innan du bestämmer dig för att delta i en studie.

Intresserad av att delta?

Registrera ditt intresse

Dela dina uppgifter och forskarteamet för "MAVRiC Studies 2L Treatment With AV in Patients With CLL/SLL…" kommer att kontakta dig om du kan vara berättigad. Prata alltid med din läkare innan du går med på att delta.

Diskussion

Gemenskapsdiskussion

Drivs av vårt forum på community.patient.info. Var vänlig och respektfull — detta är inte medicinsk rådgivning.